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  ABSTRACT 
  Objective      A common deletion mapping to the 
psoriasis susceptibility locus 4 on chromosome 1q21, 
encompassing two genes of the late corniﬁ  ed envelope 
(LCE) gene cluster, has been associated with an 
increased risk of psoriasis vulgaris (PsV). One previous 
report found no association of the deletion with psoriatic 
arthritis (PsA), suggesting it may be a speciﬁ  c risk factor 
for PsV. Given the genetic overlap between PsA and PsV, 
a study was undertaken to investigate whether single 
nucleotide polymorphisms (SNPs) mapping to this locus 
are risk factors for PsA in a UK and Irish population.   
  Methods      Three SNPs with prior evidence of association 
with susceptibility to PsV were genotyped in 1057 
patients with PsA using Sequenom iPlex chemistry and 
genotype frequencies compared with data available 
for 5575 healthy controls. Two of the SNPs, rs4112788 
and rs4085613, were reported to be highly correlated 
with the LCE deletion. The third SNP, rs6701216, was 
previously reported to be associated with PsV in a US 
population.  
  Results      Alleles tagging the deletion for both 
rs4112788 and rs4085613 were found to be enriched 
in cases compared with controls (69% vs 65%) and 
signiﬁ  cantly associated with increased susceptibility to 
PsA (p  trend   = 0.001, OR 1.19 and p  trend   = 0.001, OR 
1.18, respectively). No association was observed with 
rs6701216.  
  Conclusions      The evidence presented here supports 
LCE deletion as a risk factor for PsA in a UK and Irish 
population. It suggests that this locus is a risk factor 
within a shared aetiological pathway that contributes to 
psoriatic skin disease in both PsV and PsA.           
  INTRODUCTION 
  Psoriatic arthritis (PsA) is an inﬂ  ammatory joint 
condition associated with psoriasis vulgaris (PsV); 
it is estimated that up to 30% of patients with 
PsV also have articular disease. PsA is considered 
to be a complex disease with contributions from 
both environmental and genetic risk factors.  1   The 
genetic component is estimated to be strong, with 
a sibling recurrence RR (λ  s  ) of 47 in a UK popula-
tion.  2   Genetic investigations have revealed a num-
ber of risk factors that are common to both PsV 
and PsA. These established risk loci,   HLA-Cw6  , 
  IL12B   and   IL23R  , do not allow them to be geneti-
cally discriminated.  3     4   
  A number of studies have recently identiﬁ  ed 
genetic variants mapping to chromosome 1q21 
within the previously identiﬁ   ed psoriasis sus-
ceptibility locus 4  5  –  7   as being associated with 
susceptibility to PsV. A genome-wide scan for 
copy number variation identiﬁ  ed an association 
between a 32.2 kb deletion (  LCE3C_LCE3B-del  ) 
that encompasses two genes of the late corni-
ﬁ   ed envelope (LCE) gene cluster (  LCE3B   and 
  LCE3C  ), with increased susceptibility to PsV in 
multiple populations.  5   This deletion was found 
to be highly correlated with the single nucleotide 
polymorphism (SNP) rs4112788 (r  2  =0.93) with 
the major allele (C) tagging   LCE3C_LCE3B-del  . 
This association is further supported by evidence 
from an independent SNP genome-wide associa-
tion study (GWAS) for PsV that reported asso-
ciation to rs4085613 mapping to this locus.  6   The 
SNPs rs4112788 and rs4085613 are in high link-
age disequilibrium (LD) (r  2  >0.95) and, as such, 
are not considered to be independently associ-
ated. A further independent GWAS investigating 
susceptibility to PsV identiﬁ  ed an association to 
rs6701216 that maps to the   LCE1C   gene,  7   which 
represents an effect independent of rs4112788 and 
rs4085613 as there is little LD (r  2  <0.05) between 
the variants.  6   From these genetic studies alone 
it is not clear whether the deletion itself or the 
SNPs in LD with it are primarily responsible for 
the association seen, and functional studies will 
be required to determine the mechanism for the 
disease predisposition. 
  Intriguingly, unlike the previously identiﬁ  ed 
psoriasis loci,   LCE3C_LCE3B-del   and correlated 
SNPs were associated with PsV but not PsA sus-
ceptibility in a German cohort, suggesting this 
may be the ﬁ  rst risk factor identiﬁ  ed that predis-
poses to skin-type psoriasis only, implying that 
the skin disorder in PsV and PsA have differing 
underlying genetic aetiologies.  8     9   Identiﬁ  cation 
of genetic factors that differentiate the two phe-
notypes could help to reveal distinct aetiological 
pathways. Validation of such a ﬁ  nding in inde-
pendent studies is therefore essential, and the 
aim of the work presented here was to investi-
gate association with SNP markers in LD with 
  LCE3C_LCE3B-del   in a large case–control study 
of subjects with PsA and controls from the UK 
and the Republic of Ireland (ROI).   
 ▶   Additional data are published 
online only.  To view these ﬁ  les 
please visit the journal online 
(http://ard.bmj.com). 
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PsV. Stratiﬁ  cation analysis was therefore undertaken to explore 
whether any associations were restricted to one subpheno-
type. Patients with PsA are usually but not always seronegative 
for rheumatoid factor. It is possible that those with a posi-
tive rheumatoid factor are actually patients with rheumatoid 
arthritis and co-existent psoriasis, which may bias any analy-
sis. Subphenotype analysis was therefore also undertaken in 
patients with PsA seronegative for rheumatoid factor to deter-
mine whether the presence of this antibody was a signiﬁ  cant 
confounder. All subphenotype analyses were performed in 
UK samples only. No information was available regarding the 
extent of psoriasis or the presence of spondyloarthritis. 
  Finally, we analysed data from 12 autosomal SNPs identiﬁ  ed 
as showing signiﬁ  cant variation across geographical regions of 
the UK.  14   Our interpretation of these results would be that mul-
tiple associations to these SNPs is indicative of regional ascer-
tainment bias of case samples given that control samples are 
known to be collected from across the UK. This analysis was 
restricted to the UK samples.     
  RESULTS 
  Genotyping 
  All LCE SNPs demonstrated satisfactory clustering of genotypes 
with clear and highly distinct clusters. Following the applica-
tion of the data quality control criteria, the dataset consisted of 
a maximum of 982 cases and 5574 controls with a genotyping 
success rate of 99.9% in the remaining samples. The genotyping 
for the 12 SNPs with prior evidence of geographical variation 
across the UK consisted of a maximum of 819 cases and 5379 
controls following QC with a genotyping success rate of 99.9% 
in the remaining samples.   
  Statistical  analysis 
  For all LCE SNPs in the primary analysis the control sample groups 
conformed to HWE (  table 1  ). We observed similar genotype fre-
quencies for rs4112788 and rs4085613 and they were found to be 
highly correlated (D′=1, r  2  =0.99). Allele frequencies were found 
to be within the range of previously reported frequencies for the 
Caucasian population.  5     8   We observed enrichment of deletion-
correlated alleles in the case group compared with the control 
group (69% vs 65% for both SNPs). This enrichment was found 
to be signiﬁ  cantly associated with PsA susceptibility under an 
additive model (  table 1  ). The association remained when the 
analysis was restricted to the UK-only sample set (rs4112788, 
p  trend  =0.008; rs4085613, p  trend  =0.009). No association to any 
SNP was observed in the ROI-only analysis and deviation from 
HWE (p=0.02) was noted in this control group. Meta-analysis of 
the independent UK and ROI results supported the association 
(rs4112788, p=0.005; rs4085613, p=0.006) with no evidence of 
heterogeneity (Q=0.95, I  2  =0) for both SNPs. No evidence was 
found to support association to rs6701216. 
  Stratiﬁ   cation analysis did not reveal qualitatively differ-
ent associations in subgroups of patients with PsA with type 
I or type II PsV or in those seronegative for rheumatoid factor 
(  table 2  ). It is important to note that the sample numbers were 
reduced owing to incomplete phenotype data. 
  Analysis of the 12 geographical markers revealed association 
to only a single SNP, rs3873375 (p  trend  =1.53×10  −7  ) (see table 1 in 
online supplement).     
  DISCUSSION 
  We have found that SNPs previously reported to be in high LD 
with   LCE3C_LCE3B-del   on chromosome 1q21 are associated 
  METHODS 
  Patient  samples 
  Genomic DNA was available from 1057 Caucasian patients 
with PsA recruited from three UK rheumatology centres and 
one centre in the ROI (885 patients in the UK and 172 in the 
ROI), details of which have been described previously.  10  –  12   
PsA was deﬁ  ned as the presence of both psoriasis and inﬂ  am-
matory arthritis regardless of rheumatoid factor status, and all 
had peripheral arthritis. The majority of samples satisﬁ  ed the 
CASPAR (ClASsiﬁ  cation criteria for Psoriatic ARthritis) classiﬁ  -
cation system, although some were collected prior to the intro-
duction of this classiﬁ  cation system.  13     
  SNP  selection 
  We selected three SNPs for genotyping that map to the 1q21 
locus (see ﬁ  gure 1 in online supplement). Two SNPs, rs4085613 
and rs4112788, have previously been shown to be in high LD 
with   LCE3C_LCE3B-del   and were reported to be the most asso-
ciated variants from two independent studies.  5     6   The third SNP, 
rs6701216, represents a reported effect that is potentially inde-
pendent of   LCE3C_LCE3B-del  .  7   In addition, we genotyped 12 
autosomal SNPs that were reported to be informative of geo-
graphical variation across the UK.  14     
  Control  samples 
  Data for healthy controls were sourced from the Wellcome 
Trust Case-Control Consortium 2 project (www.wtccc.org.uk). 
This dataset consists of samples from the 1958 British Birth 
Cohort and the UK Blood Service Collection genotyped on the 
Illumina Human1M-Duo BeadChip or Affymetrix Human SNP 
Array 6.0. In addition, 375 control samples were available from 
the ROI.   
  Genotyping 
  SNP genotyping of the PsV and ROI control samples was per-
formed using Sequenom’s MassARRAY system (San Diego, 
California, USA) according to the manufacturer’s speciﬁ  cations 
for the iPLEX chemistry using 10 ng genomic DNA. Genotype 
cluster plots were evaluated prior to analysis to ensure satisfac-
tory assay performance.   
  Statistical  analysis 
  Statistical analyses were performed using the PLINK software 
package.  15   Quality control (QC) inclusion thresholds for both 
individual sample and SNP genotyping missing data rates were 
set at >90%. Test statistics were calculated for deviation from 
Hardy–Weinberg equilibrium (HWE) using an exact test, the 
Cochran-Armitage trend test, ORs (including 95% CI) and LD 
(r  2  ). The trend test was selected as the most appropriate genetic 
model as previous evidence in psoriasis studies suggested a dos-
age effect based on allele carriage,  5   thus providing the maximal 
power for association testing.  16   
  The primary analysis investigated the dataset in its entirety 
with UK and ROI samples treated as one common population. 
In the interests of identifying heterogeneity between the UK and 
ROI cohorts, we analysed these components separately. The 
results were subsequently combined using an inverse variance 
meta-analysis under the assumption of ﬁ  xed effects. Signiﬁ  cant 
heterogeneity between the two groups was estimated using the 
Cochran Q and I  2   statistics. 
  Previous work in PsV has found that the major genetic sus-
ceptibility locus,   HLA-Cw*06  , is associated with early onset 
(type I PsV, age at onset <40 years) but not late onset (type II) 
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with PsA in a large case–control cohort recruited from the UK 
and ROI. 
  This deletion is of particular interest for psoriatic pheno-
types as the genes of the LCE cluster encode stratum corneum 
proteins that play an important role in epidermal terminal dif-
ferentiation, disruption of which has been proposed to lead to 
abnormal differentiation and psoriatic skin lesions.  5   We did 
not ﬁ  nd evidence to support an independent association to 
rs6701216. Stratiﬁ   cation analysis by subphenotype demon-
strated no qualitative difference between type I and type II 
psoriatic subphenotypes when considering the ORs. However, 
no association was observed in the type II group, which is 
likely to be attributable to low power owing to reduced sam-
ple numbers. A stronger effect was observed in the seronega-
tive subphenotype, but this could be due to imprecision in the 
effect estimates owing to smaller sample numbers reﬂ  ected 
by the wider CIs compared with the analysis of the whole 
UK group. 
  Our ﬁ  ndings differ from the results of a recent study per-
formed in a German population which found no evidence to 
support such an association in PsA.  8     9   This discrepancy could 
be explained by any one of three scenarios. First, it may be a 
false positive (type I error) in our study. However, we have 
genotyped two highly correlated SNPs that demonstrate com-
parable results, thus making genotyping error an unlikely fac-
tor. It is also important to note that our genotype frequencies, 
p values and effect estimates for rs4112788 closely match 
recent reports supporting this locus as a risk factor for PsV.  9   
Second, it may be a false negative (type II error) in the German 
study. While the study had 95% power to detect the maximal 
reported effect size, there is still potential for type II errors 
in such well-powered studies. This point is well illustrated 
with examples from a recent GWAS in the UK.  14   This study 
failed to identify two robust rheumatoid arthritis risk loci—
tumour necrosis factor receptor-associated factor 1 and sig-
nal transducer and activator of transcription 4—which were 
subsequently conﬁ  rmed in the UK population only following 
reports from other GWAS.  17   Third, the patient demograph-
ics of the two cohorts may be substantially different. For 
example, they may consist of different proportions of type I 
and type II psoriasis or   HLA-Cw6   positivity, with association 
restricted to a particular subphenotype. This may be of par-
ticular importance if the evidence for an epistatic interaction 
between   LCE3C_LCE3B-del   and   HLA-Cw6   holds true upon 
further validation.  5      18   Although the clinical characteristics of 
the British Isles and German cohorts appear similar, we do 
not currently have the   HLA-Cw6   data that would allow us to 
thoroughly explore this possibility. 
  This study has two potential limiting factors. The ﬁ  rst is the 
risk of confounding by population stratiﬁ  cation as the cohort 
is drawn from two populations of European ancestry. This 
issue was addressed in a number of ways. First, we reduced 
the potential for heterogeneity by restricting the analysis to 
only UK samples. Both rs4112788 and rs4085613 remained 
signiﬁ   cantly associated with a marginal fall in signiﬁ  cance 
attributable to the smaller sample size. No association was 
observed in the ROI-only analysis, conceivably due the small 
sample size. Second, we attempted to control for heterogene-
ity by employing an inverse variance meta-analysis on sum-
mary statistics from the individual UK and ROI dataset. Both 
SNPs retained signiﬁ  cant evidence for association with no evi-
dence for heterogeneity, thus supporting the use of a combined 
dataset. Although the Cochran Q and I  2   test statistics are not 
informative of underlying population structure, they would 
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reveal differences in allele frequencies between the groups 
with the potential to confound. Finally, in the UK cohort we 
analysed 12 autosomal SNPs known to be informative of geo-
graphical region. Only one SNP was found to be associated 
(rs3873375), but this maps 11 kb upstream of   HLA-C   which is 
a known PsV risk locus. From this we conclude that there is no 
evidence of regional ascertainment bias between the UK case 
and control groups. More sophisticated forms of correction 
for population stratiﬁ  cation do exist—for example, correcting 
with principal component analysis.  19   However, these methods 
typically require dense SNP datasets, such as those emerging 
from GWAS, which are currently not available for this cohort. 
Given the frequency differences between the UK and ROI con-
trols, the most robust association statistics could be considered 
to be those emerging from the UK-only analysis based on the 
larger sample size. 
  The second potential issue is that our study did not directly 
type   LCE3C_LCE3B-del  , but we did genotype two SNPs 
shown in previous studies to be in high LD with the deletion 
(rs4112788; r  2  >0.90).  5     9   The use of SNPs as accurate proxies for 
deletions is supported by evidence from studies exploring their 
relationship on a genome-wide scale.  20   The use of high quality 
data for the deletion would represent the ideal scenario as any 
deviation of the proxy from perfect LD would result in the loss 
of power. However, studies have highlighted the technical dif-
ﬁ  culties involved in the accurate typing of copy number variants 
using methods such as quantitative PCR and the paralogue ratio 
test.  21   Indeed, the accurate genotyping of   LCE3C_LCE3B-del   in 
a recent PsV study required the application of multiple methods 
to achieve an acceptable success rate.  9   We therefore preferred 
the robust technology of SNP genotyping, accepting a potential 
minor reduction of power. 
  Assessing the published reports to date, it is unclear if the 
causal variants are SNPs, the deletion or a tagged unknown 
variant. A comprehensive ﬁ  ne mapping study of the region is 
therefore required that incorporates both SNPs and structural 
variation in order to identify the causal variant(s) before proceed-
ing to functional studies aimed at understanding the mechanism 
by which the variants predispose to PsV, and whether these dif-
fer in any way from those predisposing to PsA. In turn, this may 
open up the possibility of different therapies being developed 
based on the novel target. 
  In conclusion, this study provides further genetic support that 
the psoriasis seen in dermatology clinics does not differ from 
that seen by rheumatologists, and that patients with PsA can be 
included in genetic studies of psoriasis per se. This example also 
further illustrates the importance of large sample sizes for the 
detection of the modest effect sizes typical of complex traits.         
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  Table  2          Summary of results for phenotype subgroup analysis   
 SNP   Genotype 
  Type I psoriasis (n=519)    Type II psoriasis (n=176)   Seronegative  (n=328) 
 Count  (frq)   p   trend    OR  (CI)   Count  (frq)   p   trend    OR  (CI)   Count  (frq)   p   trend    OR  (CI) 
rs4085613 CC 234 (45.2)   1.16 (1.01 to 1.33) 85 (48.3)   1.15 (0.92 to 1.45) 157 (47.9)   1.23 (1.04 to 1.47)
CA 240 (46.3) 0.03 70 (39.8) 0.22 143 (43.6) 0.015
AA   44 (8.3)   21 (11.9)     28 (8.5)  
rs4112788 CC 233 (44.9)   1.16 (1.01 to 1.33) 85 (48.3)   1.17 (0.93 to 1.47) 156 (47.6)   1.24 (1.04 to 1.47)
CT 243 (46.8) 0.03 71 (40.3) 0.18 145 (44.2) 0.014
TT  43  (8.3)   20 (11.4)    27  (8.2)  
      Control frequencies are those reported in the UK analysis reported in   table 1  . 
  frq, frequency; n, number in subgroup; SNP, single nucleotide polymorphism.     
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